These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18590464)

  • 41. Antileishmanial effects of clofazimine and other antimycobacterial agents.
    Evans AT; Croft SL; Peters W; Neal RA
    Ann Trop Med Parasitol; 1989 Oct; 83(5):447-54. PubMed ID: 2619361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmaceutical agents for treatment of leishmaniasis: a patent landscape.
    Barbosa Gomes de Carvalho YM; Shanmugam S; Batista MS; Serafini MR; Araújo AAS; Quintans Júnior LJ
    Expert Opin Ther Pat; 2020 Aug; 30(8):633-641. PubMed ID: 32602760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems.
    Kozlovskaya L; Stepensky D
    J Control Release; 2013 Oct; 171(1):17-23. PubMed ID: 23831053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.
    Date AA; Joshi MD; Patravale VB
    Adv Drug Deliv Rev; 2007 Jul; 59(6):505-21. PubMed ID: 17574295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
    Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases.
    Zucca M; Scutera S; Savoia D
    Curr Med Chem; 2013; 20(4):502-26. PubMed ID: 23210775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Overview of the Compounds Tested In Vivo for Leishmania spp. of the Last 5 Years.
    de Barros Dias MCH; Freitas LAB; Dos Santos IR; de Almeida VS; do Amaral E Melo RT; de Melo Silva VG; de Fátima Maia de Santana B; da Conceição JM; Lima Leite AC
    Curr Med Chem; 2021; 28(21):4226-4258. PubMed ID: 33198609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of Tridax procumbens against promastigotes of Leishmania mexicana.
    Martín-Quintal Z; Moo-Puc R; González-Salazar F; Chan-Bacab MJ; Torres-Tapia LW; Peraza-Sánchez SR
    J Ethnopharmacol; 2009 Apr; 122(3):463-7. PubMed ID: 19429313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations.
    Abamor ES; Allahverdiyev AM
    Exp Parasitol; 2016 Jul; 166():150-63. PubMed ID: 27109311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
    Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Formulation and Characterization of a Self-Emulsifying Drug Delivery System (SEDDS) of Curcumin for the Topical Application in Cutaneous and Mucocutaneous Leishmaniasis.
    Khan M; Nadhman A; Sehgal SA; Siraj S; Yasinzai MM
    Curr Top Med Chem; 2018; 18(18):1603-1609. PubMed ID: 30360717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delivery strategies for antiparasitics.
    Kayser O; Kiderlen AF
    Expert Opin Investig Drugs; 2003 Feb; 12(2):197-207. PubMed ID: 12556214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
    Kar N; Chakraborty S; De AK; Ghosh S; Bera T
    Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced activity of antisense phosphorothioate oligos against leishmania amastigotes: augmented uptake of oligo, ribonuclease H activation, and efficient target intervention under altered growth conditions.
    Mishra M; Porter-Kelley JM; Singh PK; Bennett JR; Chaudhuri G
    Biochem Pharmacol; 2001 Sep; 62(5):569-80. PubMed ID: 11585054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New approaches from nanomedicine for treating leishmaniasis.
    Gutiérrez V; Seabra AB; Reguera RM; Khandare J; Calderón M
    Chem Soc Rev; 2016 Jan; 45(1):152-68. PubMed ID: 26487097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in the treatment of leishmaniasis.
    Sundar S; Rai M
    Curr Opin Infect Dis; 2002 Dec; 15(6):593-8. PubMed ID: 12821836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conventional Versus Natural Alternative Treatments for Leishmaniasis: A Review.
    Passero LFD; Cruz LA; Santos-Gomes G; Rodrigues E; Laurenti MD; Lago JHG
    Curr Top Med Chem; 2018; 18(15):1275-1286. PubMed ID: 30277153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
    Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
    Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
    Tempone AG; Mortara RA; de Andrade HF; Reimão JQ
    Int J Antimicrob Agents; 2010 Aug; 36(2):159-63. PubMed ID: 20554161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.